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Invasive candidiasis remains a dreadful complication in
hospitalized patients, generally associated with poor
prognosis [1, 2]. Except in the case of candidemia, it is
difficult to diagnose. In contrast to Aspergillus spp., bi-
ological tools have not been developed to diagnose
candidiasis [3], and using the current clinical and mi-
crobiological criteria the threshold between colonization
and infection may be difficult to distinguish [4]. Risk
factors including colonization predispose to the devel-
opment of invasive candidiasis in both immunocompro-
mised and nonimmunocompromised patients [5, 6, 7].
However, as a majority of them are directly linked to an
underlying disease or its treatments, it is almost impos-
sible to target them for prevention. The high proportion
of bone marrow transplant recipients developing can-
didiasis has stimulated clinical research which has es-
tablished the value of antifungal prophylaxis. Azole-
based prophylaxis has progressively imposed as a stan-
dard of care for severely neutropenic patients [8] and in
most solid-organ transplant recipients [9]. However, an-
tifungal prophylaxis has been repeatedly implicated in
the increasing proportion of non-albicans Candida iso-
lated in many cancer centers [10, 11]. This has generated
a considerable debate, and guidelines have been modified
accordingly [12].
This is not the case in nonimmunocompromised criti-
cally ill patients, in whom international surveillance
programs have shown that C. albicans remains the pre-
dominant strain in most countries [13]. Moreover, this is
also the case in almost all recent series on candidiasis in
ICU patients [14, 15, 16, 17]. Several characteristics of
these patients may have a strong impact on this ecology.
ICU patients present many risk factors for invasive can-
didiasis. In particular, a high proportion of them become
colonized with Candida spp., but only a minority develop
invasive candidiasis. However, related to its poor prog-
nosis, the difficulty in identifying subgroups of patients
that could benefit from prophylaxis, and to the good se-
curity profile of azoles, it may be tempting to treat sys-
tematically all colonized patients. According to the ex-
perience acquired with immunocompromised patents, this
should be avoided.
Colonization by Candida spp. is an independent risk
factor for candidiasis. As assessed by the colonization
index proposed by Pittet and confirmed by others [14, 15,
16], increasing growth of Candida spp. from multiple
body sites is predictive of subsequent invasive candidia-
sis. Despite several studies in critically ill nonimmuno-
suppressed patients [14, 15, 16, 17] antifungal prophy-
laxis has been insufficiently validated and is currently not
included in most published guidelines. However, a sys-
tematic review and meta-analysis of these studies just
published in Intensive Care Medicine Journal shows a
significantly reduced rate of candidiasis, overall mortali-
ty, and cases attributable to candidiasis [18]. This con-
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firms the proposal of some experts to consider prophy-
laxis in these patients. All these authors recommend
strictly restricting them to high-risk patients [14, 15, 16,
17, 18]. However, such patients are difficult to identify.
Identifying them relies on sophisticated and nonvalidated
clinical approaches combining the presence of nonspe-
cific risk factors and on the dynamic of colonization by
Candida [4].
The study performed by Normand et al. [19] now
published in Intensive Care Medicine suggests a novel
way in which to prevent invasive candidiasis in critically
ill patients. The open-label study randomized 98 patients
mechanically ventilated for more than 48 h to receive oral
prophylaxis by nystatin or a placebo. No invasive can-
didiasis developed, but prophylaxis significantly reduced
the colonization index and prevented colonization. The
absence of invasive candidiasis was due to the selection
of patients at low risk of developing such complication.
The severity score at study entry, proportion of patients
colonized at entry, and mean value of the colonization
index were lower than in other prophylactic studies [14,
15, 16, 17]. This confirms that low-risk patients are
characterized by a low proportion of colonization and by
a persistent low value of the colonization index over time.
Moreover, persistently low values of the colonization
index strongly suggested that prophylaxis interferes with
the dynamic of colonization by Candida spp. in patients
receiving nystatin.
Nystatin, as with amphotericin B, is a nonabsorbable
polyene with a wide antifungal activity, especially against
Candida spp., including C. glabrata and C. krusei. Pro-
phylaxis with nystatin has often been disappointing in
immmunocompromised patients, and a meta-analysis
found no differences to placebo in colonization or mor-
tality [20]. However, the dose of nystatin and method of
administration differed across studies, precluding com-
parisons of efficacy.
A nonabsorbable drug may present an elegant alter-
native to the complex and difficult selection of patients at
high risk who could benefit from antifungal prophylaxis.
The results reported by Normand et al. are the first sug-
gesting a potential efficacy of nystatin prophylaxis in
nonimmunocompromised ICU patients. However, it
should be remembered that selective decontamination of
the digestive tract (SDD) is aimed to prevent nosocomial
infection in ICU patients, including those caused by fungi.
Nonabsorbable polyenes are integrated in most SDD
regimens, and a recent meta-analysis showed that they
significantly reduce fungal carriage and overall fungal
infections, but without impact on fungemia. However,
only few trials were available for analysis of fungal car-
riage and the definitions of fungal infections were het-
erogeneous [21].
In critically nonimmunocompromised patients several
advantages may favor the use of nystatin instead of azoles
as a prophylactic antifungal regimen. First, a nonab-
sorbable molecule, different from other drugs available
for treatment, is an attractive concept. As indicated above,
although most species of Candida isolated in ICU patients
remain susceptible to azoles, indiscriminate use of such
drugs may lead to the spread of C. krusei and C. glabrata,
intrinsically resistant and dose-dependent sensitive to
azoles, respectively. In contrast, primary resistance to
polyenes among Candida spp. is limited to C. lusitaniae
and to some strains of C. guillermondii, and resistance
seldom develops during treatment. Therefore polyene
prophylaxis is less likely to promote the emergence of
resistant strains of Candida. Second, Normand et al. did
not observe adverse effects of nystatin. Azoles are gen-
erally well tolerated, but side effects such as hepatic
dysfunction are possible. These risks, even if low, could
be more difficult to accept in the setting of prophylaxis in
critically ill patients. The third advantage of oral nystatin
is its low cost, making this strategy potentially highly cost
effective—if it works!
Accordingly, as suggested by the authors, these pre-
liminary data should stimulate the medical community to
explore the usefulness of oral nystatin prophylaxis in
other groups of critically ill patients at higher risk. If
confirmed, such approach may contribute to solve ongo-
ing controversies in the field of prevention of invasive
candidiasis in nonimmunocompromised critically ill pa-
tients.
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